NCT05683444 is a EARLY_PHASE1 clinical trial of Octreotide infusion in Lymphatic Diseases, sponsored by Rigshospitalet, Denmark.

Who is sponsoring NCT05683444?

NCT05683444 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT05683444?

Interventions in NCT05683444: Octreotide infusion, Saline infusion.

What condition does NCT05683444 study?

NCT05683444 studies Lymphatic Diseases, Chylothorax.

Is NCT05683444 still recruiting?

NCT05683444 is currently completed. Last updated 30 March 2023.

Last reviewed 2023-03-30 · How we verify

NCT05683444

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

Completed EARLY_PHASE1 Last updated 30 March 2023

What this trial tests

EARLY_PHASE1 trial testing Octreotide infusion in Lymphatic Diseases in 16 participants. Completed in 26 March 2021.

Timeline

1 July 2020

Primary endpoint
26 March 2021

26 March 2021

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	16
Start date	1 July 2020
Primary completion	26 March 2021
Estimated completion	26 March 2021
Sites	1 location across Denmark

Drugs / interventions tested

Octreotide infusion — full drug profile →
Saline infusion — full drug profile →

Conditions studied

Lymphatic Diseases — all drugs for Lymphatic Diseases →
Chylothorax — all drugs for Chylothorax →

Sponsor

Rigshospitalet, Denmark

Who can join

Adults 20 to 35, any sex, with Lymphatic Diseases or Chylothorax. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. To study the effects of octreotide, the researchers conducted a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and other lymphatic disorders.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Octreotide improves human lymphatic fluid transport a translational trial.
Holm-Weber T, Skov F, Mohanakumar S, Thorup L, et al · · 2024 · cited 1× · PMID 37951584 · DOI 10.1093/ejcts/ezad380

Verify or expand the search:

Other recruiting trials for Lymphatic Diseases

Currently open trials in the same condition.

NCT05731141 — A Prospective Natural History Study of Lymphatic Anomalies · recruiting
NCT05263583 — Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma · Phase 2 · active not recruiting
NCT05441943 — Lymphaticovenous Anastomosis as Treatment for Lymphedema · NA · active not recruiting
NCT03696784 — Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma · Phase 1 · active not recruiting
NCT03602157 — Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL · Phase 1 · active not recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05683444 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 30 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05683444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing